MPMargaret A. Phillips

Margaret A. Phillips

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Margaret A. Phillips has a total of 372 co-authors. Here are the top co-authors by number of shared publications:

  • Xiaoyi Deng

    Department of Biochemistry

    17 shared publications
  • Farah El Mazouni

    Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States

    16 shared publications
  • Susan A. Charman

    Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia

    15 shared publications
  • John White

    Department of Chemistry, University of Washington, Seattle, Washington 98195, United States

    14 shared publications
  • Pradipsinh K. Rathod

    Department of Chemistry, University of Washington, Seattle, Washington 98195, United States

    13 shared publications
  • Sreekanth Kokkonda

    Department of Chemistry, University of Washington, Seattle, Washington 98195, United States

    11 shared publications

Latest Publications

  • Optimization of Species-Selective Reversible Proteasome Inhibitors for the Treatment of Malaria

    by Suraksha Gahalawat, Sneha Ray, Xiaoyu Zhang, Xiaoyi Deng, Yan Han, Zhe Chen, Aloysus Lawong, David M. Shackleford, Kasiram Katneni, Gong Chen, et al.

    Malaria remains a critical global health challenge, with increasing resistance to frontline therapies necessitating novel drug targets. The proteasome has emerged as a promising target for antimalarial drug discovery. This study describes efforts to optimize a series of species-selective reversible inhibitors targeting the Plasmodium falciparum 20S proteasome. Starting from the carboxypiperidine scaffold identified through a high-throughput viability screen, we conducted iterative structure-activity relationship studies, leading to the development of highly potent and selective inhibitors with good oral bioavailability. Lead compounds demonstrated nanomolar potency against P. falciparum blood-stage parasites and selective inhibition of the parasite proteasome over the human counterpart. Cryo-EM structural studies confirmed binding at the β5 subunit, while in vivo pharmacokinetic studies identified promising candidates for further development. These findings support proteasome inhibition as a viable strategy for novel antimalarial drug development.


  • Open Access

    Identification of α-Azacyclic Acetamide-Based Inhibitors of P. falciparum Na + Pump ( Pf ATP4) with Fast-Killing Asexual Blood-Stage Antimalarial Activity by Phenotypic Screening

    by Arturo Casas Jr, Leah S. Imlay, Vandana Thathy, Kate J. Fairhurst, Adele M. Lehane, Aloysus K. Lawong, Ioanna Deni, Josefine Striepen, Seungheon Lee, Ashwani Kumar, et al.

    Malaria treatments are compromised by drug resistance, creating an urgent need to discover new drugs. We used a phenotypic high-throughput screening (HTS) platform to identify new antimalarials, uncovering three related pyrrole-, indole-, and indoline-based series with a shared α-azacyclic acetamide core. These compounds showed fast-killing activity on asexual blood-stage Plasmodium falciparum parasites, were not cytotoxic, and disrupted parasite intracellular pH and Na+ regulation similarly to cipargamin (KAE609), a clinically advanced inhibitor of the P. falciparum Na+ pump (PfATP4). PfATP4 is localized to the parasite plasma membrane and is essential for maintaining a low cytosolic Na+ concentration. Resistance selections on P. falciparum parasites with two α-azacyclic acetamide analogs identified mutations in PfATP4, and cross-resistance was observed across the α-azacyclic acetamides and KAE609, confirming PfATP4 as the target. PfATP4 is a well-established antimalarial target, and identification of additional PfATP4 inhibitors provides alternative avenues to disrupt its function.


  • Open Access

    Optimization of species-selective reversible proteasome inhibitors for the treatment of malaria

    by Suraksha Gahalawat, Sneha Ray, Xiaoyu Zhang, Xiaoyi Deng, Yan Han, Zhe Chen, Aloysus Lawong, David Shackleford, Kasiram Katneni, Gong Chen, et al.

    Malaria remains a critical global health challenge, with increasing resistance to frontline therapies necessitating novel drug targets. The proteasome has emerged as a promising target for antimalarial drug discovery. This study describes efforts to optimize a series of species-selective reversible inhibitors targeting the Plasmodium falciparum 20S proteasome. Starting from the carboxypiperidine scaffold identified through a high-throughput viability screen, we conducted iterative structure-activity relationship studies, leading to the development of highly potent and selective inhibitors with good oral bioavailability. Lead compounds demonstrated nanomolar potency against P. falciparum blood-stage parasites and selective inhibition of the parasite proteasome over the human counterpart. Cryo-EM structural studies confirmed binding at the β5 subunit, while in vivo pharmacokinetic studies identified promising candidates for further development. These findings support proteasome inhibition as a viable strategy for novel antimalarial drug development

  • Open Access

    The Pseudomonas aeruginosa Type VI secretion system toxin Tse8 evolved from a novel N-carbamoylputrescine amidohydrolase

    by Bin Li, Hamid R. Baniasadi, Margaret A. Phillips, Anthony J. Michael

    The polyamine putrescine is synthesized primarily from L-arginine via agmatine in bacteria. There are currently three known routes from agmatine to putrescine, including direct conversion by agmatinase. The other two routes use agmatine deiminase to produce N-carbamoylputrescine from agmatine, then one of two nonhomologous enzymes, putrescine transcarbamylase or N-carbamoylputrescine amidohydrolase (NCPAH) convert N-carbamoylputrescine to putrescine. Here, we functionally identify enzymes from phylogenetically distant bacteria, the gamma-proteobacterium Shewanella oneidensis, and the actinomycetota species Microterricola gilva, that are novel alternative, nonhomologous, noncanonical NCPAHs that we term AguY, which have emerged by convergent evolution. Kinetic analysis indicates that the AguY enzymes are as efficient as the canonical NCPAH from Pseudomonas aeruginosa, in converting N-carbamoylputrescine to putrescine. Genomic evidence suggests that the AguY enzymes may participate in putrescine biosynthetic or agmatine catabolic pathways, and are occasionally encoded in genomes that also encode agmatinase. We show that the Type VI secretion system toxin Tse8 from Pseudomonas aeruginosa has evolved from AguY. It is formally possible that AguY evolved directly or indirectly from the ancient glutamine amidohydrolase GatA, a component of the transamidosome, an RNA/protein complex required for production of glutamine-charged tRNA. Our study provides a further example of the prevalence of convergent evolution and horizontal gene transfer in polyamine biosynthesis, suggesting pervasive selective pressure to evolve polyamine metabolism in bacteria.


  • Open Access

    Identification of α-azacyclic acetamide-based inhibitors of P. falciparum Na + pump ( Pf ATP4) with fast-killing asexual blood-stage antimalarial activity by phenotypic screening

    by Arturo Casas, Leah S. Imlay, Vandana Thathy, Kate J. Fairhurst, Adele M. Lehane, Aloysus K. Lawong, Ionna Deni, Josefine Striepen, Seungheon Lee, Ashwani Kumar, et al.

    Malaria treatments are compromised by drug resistance, creating an urgent need to discover new drugs. We used a phenotypic high-throughput screening (HTS) platform to identify new antimalarials, uncovering three related pyrrole-, indole-, and indoline-based series with a shared α-azacyclic acetamide core. These compounds showed fast-killing activity on asexual blood-stage Plasmodium falciparum parasites, were not cytotoxic, and disrupted parasite intracellular pH and Na + regulation similarly to cipargamin (KAE609), a clinically advanced inhibitor of the P. falciparum Na + pump ( Pf ATP4). Pf ATP4 is localized to the parasite plasma membrane and is essential for maintaining a low cytosolic Na + concentration. Resistance selections on P. falciparum parasites with two α-azacyclic acetamide analogs identified mutations in Pf ATP4, and cross-resistance was observed across the α-azacyclic acetamides and KAE609, confirming Pf ATP4 as the target. Pf ATP4 is a well-established antimalarial target, and identification of additional Pf ATP4 inhibitors provides alternative avenues to disrupt its function.

  • Open Access

    Structure-Based Discovery and Development of Highly Potent Dihydroorotate Dehydrogenase Inhibitors for Malaria Chemoprevention

    by Zhe Nie, Roger Bonnert, Jet Tsien, Xiaoyi Deng, Christopher Higgs, Farah El Mazouni, Xiaoyu Zhang, Renzhe Li, Nhi Ho, Victoria Feher, et al.

    Malaria remains a serious global health challenge, yet treatment and control programs are threatened by drug resistance. Dihydroorotate dehydrogenase (DHODH) was clinically validated as a target for treatment and prevention of malaria through human studies with DSM265, but currently no drugs against this target are in clinical use. We used structure-based computational tools including free energy perturbation (FEP+) to discover highly ligand efficient, potent, and selective pyrazole-based Plasmodium DHODH inhibitors through a scaffold hop from a pyrrole-based series. Optimized pyrazole-based compounds were identified with low nM-to-pM Plasmodium falciparum cell potency and oral activity in a humanized SCID mouse malaria infection model. The lead compound DSM1465 is more potent and has improved absorption, distribution, metabolism and excretion/pharmacokinetic (ADME/PK) properties compared to DSM265 that support the potential for once-monthly chemoprevention at a low dose. This compound meets the objective of identifying compounds with potential to be used for monthly chemoprevention in Africa to support malaria elimination efforts.


  • Open Access

    Identification of potent and reversible piperidine carboxamides that are species-selective orally active proteasome inhibitors to treat malaria

    by Aloysus Lawong, Suraksha Gahalawat, Sneha Ray, Nhi Ho, Yan Han, Kurt E. Ward, Xiaoyi Deng, Zhe Chen, Ashwani Kumar, Chao Xing, et al.


  • Open Access

    Modular Total Synthesis of the 5/5-Spirocyclic Spiroindimicins

    by Ankush Banerjee, Tiffany Brisco, Sneha Ray, Arani Datta, Xiaoyu Zhang, Zhen Zhang, Alexander Busse, Hanspeter Niederstrasser, Krissty Sumida, Bruce Posner, et al.

    Total syntheses of the 5/5-spirocyclic indoline alkaloids spiroindimicins B, C, D, E, F, and G have been achieved via a modular approach. Our route features direct coupling of halogenated pyrrolemetal and isatin partners, Suzuki coupling to append the indole unit, Lewis acid-mediated spirocyclization, and divergent functionalization to various family members. These syntheses are concise (6–7 steps from commercial materials), scalable, and highly amenable to analogue synthesis. Further studies of the antiparasitic properties of this class have revealed promising activity against T. brucei for certain congeners. Together with our prior approach to 6/5-family members, our work constitutes a synthetic solution to all known spiroindimicin natural products.


  • Open Access

    WITHDRAWN: Knockout of HD domain 5’-nucleotidase in T. brucei triggers cell death linked to DNA damage and downregulation of glutamine uptake

    by Yue Wen Deng, Michael A. Pontikos, Hamid Baniasadi, Noelle S. Williams, Margaret A. Phillips

    African trypanosomiasis is a fatal vector-borne disease caused by the protozoal parasite Trypanosoma brucei. This parasite encodes both de novo and salvage pathways for pyrimidine nucleotide biosynthesis, but in contrast to other eukaryotes, it lacks a dedicated enzyme to interconvert between cytidine (C) and uridine (U) nucleotide pools. Instead, we previously reported that nucleotide interconversion was mediated by thymidine kinase (TK) and an unknown 5’-nucleotidase enzyme. T. brucei encodes multiple potential 5’-nucelotidases, including one from the histidine-aspartate (HD) family (5’-HDNT) and two from the haloacid dehalogenase (HAD1 and HAD2) superfamily of metalloenzymes, but their relative roles and function in nucleotide metabolism remained unexplored. Herein we report that enzymes from both families catalyze dephosphorylation of pyrimidine monophosphate nucleotides, but only 5’-HDNT exhibited high activity on dCMP and was essential for T. brucei growth, while HAD1 and HAD2 were dispensable. Growth arrest upon loss of 5’-HDNT expression was rescued by ectopic expression of human dCMP deaminase (HsDCTD), which creates an alternate route for conversion between C and U pools. Knockout of 5’-HDNT led to depletion of pyrimidine pathway metabolites, altered ratios of pyrimidine to purine nucleotides, and DNA damage. Surprisingly, intracellular glutamine, the precursor of de novo pyrimidine biosynthesis, was also significantly reduced, and isotope tracing assays identified a deficiency in glutamine uptake, suggesting that the glutamine transporter was downregulated in response to loss of 5’-HDNT. This response would likely exacerbate perturbation of pyrimidine pathway homeostasis, suggesting we have uncovered a potential regulated cell death pathway in T. brucei. Author Summary Trypanosome parasites cause fatal neurologic disease if untreated, and over 50 million people in tropical and subtropical countries are at risk for contracting the disease. Current treatments suffer from toxic side effects or involve complicated therapies. Further understanding of trypanosome biology is necessary to inform new drug development efforts. Here we show that the pyrimidine biosynthesis pathway contains 5’-nucleotidases that facilitate recycling between monophosphate nucleotide and nucleoside pools, and this interconversion is essential to parasite survival. Cells lacking 5’-HDNT experience nucleotide imbalance and DNA strand breaks. Rather than increasing nutrient uptake to repair the damage, we observe downregulation of glutamine uptake and subsequent cell death. This unexpected result points to an unexplored parasite stress response pathway that could be exploited for development of new therapies.

  • Open Access

    Functional polyamine metabolic enzymes and pathways encoded by the virosphere

    by Bin Li, Jue Liang, Hamid R. Baniasadi, Margaret A. Phillips, Anthony J. Michael

    Viruses produce more viruses by manipulating the metabolic and replication systems of their host cells. Many have acquired metabolic genes from ancestral hosts and use the encoded enzymes to subvert host metabolism. The polyamine spermidine is required for bacteriophage and eukaryotic virus replication, and herein, we have identified and functionally characterized diverse phage- and virus-encoded polyamine metabolic enzymes and pathways. These include pyridoxal 5′-phosphate (PLP)-dependent ornithine decarboxylase (ODC), pyruvoyl-dependent ODC and arginine decarboxylase (ADC), arginase, S -adenosylmethionine decarboxylase (AdoMetDC/ speD ), spermidine synthase, homospermidine synthase, spermidine N -acetyltransferase, and N -acetylspermidine amidohydrolase. We identified homologs of the spermidine-modified translation factor eIF5a encoded by giant viruses of the Imitervirales . Although AdoMetDC/ speD is prevalent among marine phages, some homologs have lost AdoMetDC activity and have evolved into pyruvoyl-dependent ADC or ODC. The pelagiphages that encode the pyruvoyl-dependent ADCs infect the abundant ocean bacterium Candidatus Pelagibacter ubique , which we have found encodes a PLP-dependent ODC homolog that has evolved into an ADC, indicating that infected cells would contain both PLP- and pyruvoyl-dependent ADCs. Complete or partial spermidine or homospermidine biosynthetic pathways are found encoded in the giant viruses of the Algavirales and Imitervirales , and in addition, some viruses of the Imitervirales can release spermidine from the inactive N -acetylspermidine. In contrast, diverse phages encode spermidine N -acetyltransferase that can sequester spermidine into its inactive N -acetyl form. Together, the virome-encoded enzymes and pathways for biosynthesis and release or biochemical sequestration of spermidine or its structural analog homospermidine consolidate and expand evidence supporting an important and global role of spermidine in virus biology.